Sanofi and Regeneron score asthma hit with dupilumab

PARIS (Reuters) - Sanofi and Regeneron's biotech drug dupilumab scored a hit in treating severe asthma, clinical trial data showed on Monday, raising competition in an expected multibillion-dollar market.